Bcl-xL antagonist 2
Modify Date: 2024-01-12 10:50:03
Bcl-xL antagonist 2 structure
|
Common Name | Bcl-xL antagonist 2 | ||
|---|---|---|---|---|
| CAS Number | 1235032-75-3 | Molecular Weight | 436.51 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H16N4O3S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Bcl-xL antagonist 2Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2]. |
| Name | Bcl-xL antagonist 2 |
|---|
| Description | Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2]. |
|---|---|
| Related Catalog | |
| Target |
0.091 μM (BCL-XL)[1] |
| In Vivo | Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat[1]. iv (1 mg/kg) po (5 mg/kg) CLp (mL/min/kg) Vss (L/kg) t 1/2 (h) F % 0.47 0.16 6.0 16 |
| References |
| Molecular Formula | C21H16N4O3S2 |
|---|---|
| Molecular Weight | 436.51 |